Mastocytosis- a mutated KIT receptor induced myeloproliferative disorder

Anindya Chatterjee, Joydeep Ghosh, Reuben Kapur

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Although more than 90% systemic mastocytosis (SM) patients express gain of function mutations in the KIT receptor, recent next generation sequencing has revealed the presence of several additional genetic and epigenetic mutations in a subset of these patients, which confer poor prognosis and inferior overall survival. A clear understanding of how genetic and epigenetic mutations cooperate in regulating the tremendous heterogeneity observed in these patients will be essential for designing effective treatment strategies for this complex disease. In this review, we describe the clinical heterogeneity observed in patients with mastocytosis, the nature of relatively novel mutations identified in these patients, therapeutic strategies to target molecules downstream from activating KIT receptor and finally we speculate on potential novel strategies to interfere with the function of not only the oncogenic KIT receptor but also epigenetic mutations seen in these patients.

Original languageEnglish
Pages (from-to)18250-18264
Number of pages15
JournalOncotarget
Volume6
Issue number21
StatePublished - 2015

Fingerprint

Mastocytosis
Myeloproliferative Disorders
Mutation
Epigenomics
Systemic Mastocytosis
Survival
Therapeutics

Keywords

  • Alternative targets in mastocytosis
  • KIT mutations
  • Mastocytosis
  • Myeloproliferative disorder
  • Signaling pathways in mastocytosis

ASJC Scopus subject areas

  • Oncology

Cite this

Mastocytosis- a mutated KIT receptor induced myeloproliferative disorder. / Chatterjee, Anindya; Ghosh, Joydeep; Kapur, Reuben.

In: Oncotarget, Vol. 6, No. 21, 2015, p. 18250-18264.

Research output: Contribution to journalArticle

Chatterjee, A, Ghosh, J & Kapur, R 2015, 'Mastocytosis- a mutated KIT receptor induced myeloproliferative disorder', Oncotarget, vol. 6, no. 21, pp. 18250-18264.
Chatterjee, Anindya ; Ghosh, Joydeep ; Kapur, Reuben. / Mastocytosis- a mutated KIT receptor induced myeloproliferative disorder. In: Oncotarget. 2015 ; Vol. 6, No. 21. pp. 18250-18264.
@article{96d3e49073064daaa004ba87fea979a8,
title = "Mastocytosis- a mutated KIT receptor induced myeloproliferative disorder",
abstract = "Although more than 90{\%} systemic mastocytosis (SM) patients express gain of function mutations in the KIT receptor, recent next generation sequencing has revealed the presence of several additional genetic and epigenetic mutations in a subset of these patients, which confer poor prognosis and inferior overall survival. A clear understanding of how genetic and epigenetic mutations cooperate in regulating the tremendous heterogeneity observed in these patients will be essential for designing effective treatment strategies for this complex disease. In this review, we describe the clinical heterogeneity observed in patients with mastocytosis, the nature of relatively novel mutations identified in these patients, therapeutic strategies to target molecules downstream from activating KIT receptor and finally we speculate on potential novel strategies to interfere with the function of not only the oncogenic KIT receptor but also epigenetic mutations seen in these patients.",
keywords = "Alternative targets in mastocytosis, KIT mutations, Mastocytosis, Myeloproliferative disorder, Signaling pathways in mastocytosis",
author = "Anindya Chatterjee and Joydeep Ghosh and Reuben Kapur",
year = "2015",
language = "English",
volume = "6",
pages = "18250--18264",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "21",

}

TY - JOUR

T1 - Mastocytosis- a mutated KIT receptor induced myeloproliferative disorder

AU - Chatterjee, Anindya

AU - Ghosh, Joydeep

AU - Kapur, Reuben

PY - 2015

Y1 - 2015

N2 - Although more than 90% systemic mastocytosis (SM) patients express gain of function mutations in the KIT receptor, recent next generation sequencing has revealed the presence of several additional genetic and epigenetic mutations in a subset of these patients, which confer poor prognosis and inferior overall survival. A clear understanding of how genetic and epigenetic mutations cooperate in regulating the tremendous heterogeneity observed in these patients will be essential for designing effective treatment strategies for this complex disease. In this review, we describe the clinical heterogeneity observed in patients with mastocytosis, the nature of relatively novel mutations identified in these patients, therapeutic strategies to target molecules downstream from activating KIT receptor and finally we speculate on potential novel strategies to interfere with the function of not only the oncogenic KIT receptor but also epigenetic mutations seen in these patients.

AB - Although more than 90% systemic mastocytosis (SM) patients express gain of function mutations in the KIT receptor, recent next generation sequencing has revealed the presence of several additional genetic and epigenetic mutations in a subset of these patients, which confer poor prognosis and inferior overall survival. A clear understanding of how genetic and epigenetic mutations cooperate in regulating the tremendous heterogeneity observed in these patients will be essential for designing effective treatment strategies for this complex disease. In this review, we describe the clinical heterogeneity observed in patients with mastocytosis, the nature of relatively novel mutations identified in these patients, therapeutic strategies to target molecules downstream from activating KIT receptor and finally we speculate on potential novel strategies to interfere with the function of not only the oncogenic KIT receptor but also epigenetic mutations seen in these patients.

KW - Alternative targets in mastocytosis

KW - KIT mutations

KW - Mastocytosis

KW - Myeloproliferative disorder

KW - Signaling pathways in mastocytosis

UR - http://www.scopus.com/inward/record.url?scp=84938804012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938804012&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 18250

EP - 18264

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 21

ER -